Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sotatercept added to background therapy in high-risk pulmonary arterial hypertension
2023-509140-10-00Phase 3Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Sotatercept + background PAH therapy with Placebo + background PAH therapy (2 arms). Primary endpoint: Time to first composite morbidity/mortality event. Started Aug 2024; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-509140-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509140-10-00.